Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
643 participants
OBSERVATIONAL
2014-07-31
2017-03-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Indication: For which reasons is the indication for implantation of LAA-Occluder put for patients with atrial fibrillation?
* Safety: How save is the implantation of LAA-Occluders?
* Effectiveness: How effective is implantation of LAA-Occluders in daily clinical practice?
* Concomitant treatment: Which concomitant treatment is prescribed for patients with LAA-Occluder?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.
NCT04298723
Interventional Strategies in Treatment of Atrial Fibrillation: Percutaneous Closure of the Left Atrial Appendage Versus Catheter Ablation
NCT01363895
Safety and Efficacy of Left Atrial Appendage Occlusion Devices
NCT01695564
Left Atrial Appendage (LAA) Occluders After Catheter Ablation of Atrial Fibrillation
NCT01695824
ACT-Measurement at Different Location During Left Atrial Ablation Procedures
NCT05040035
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Indication: For which reasons is the indication for implantation of LAA-Occluder put for patients with atrial fibrillation?
* Safety: How save is the implantation of LAA-Occluders (procedural, in hospital and in the long term course)? How frequent are bleeding complications and what is the relation of observed and expected bleeding complications (according HAS-BLED score)?
* Effectiveness: How effective is implantation of LAA-Occluders in daily clinical practice (in hospital and in the long term course)? How frequent are strokes and what is the relation of observed and expected strokes (according CHADS-VASC score)?
* Concomitant treatment: Which concomitant treatment is prescribed for patients with LAA-Occluder?
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stiftung Institut fuer Herzinfarktforschung
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jochen Senges, MD
Role: PRINCIPAL_INVESTIGATOR
Stiftung Institut für Herzinfarktforschung (IHF)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinikum Coburg
Coburg, , Germany
Institut für Herzinfarkforschung Ludwigshafen
Ludwigshafen, , Germany
Universitätsmedizin Mannheim
Mannheim, , Germany
Isar Herzzentrum
München, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ansari U, Brachmann J, Lewalter T, Zeymer U, Sievert H, Ledwoch J, Geist V, Hochadel M, Schneider S, Senges J, Akin I, Fastner C. LAA occlusion is effective and safe in very high-risk atrial fibrillation patients with prior stroke: results from the multicentre German LAARGE registry. Clin Res Cardiol. 2024 Oct;113(10):1451-1462. doi: 10.1007/s00392-024-02376-8. Epub 2024 Jan 31.
Fastner C, Brachmann J, Lewalter T, Zeymer U, Sievert H, Borggrefe M, Weiss C, Geist V, Krapivsky A, Kaunicke M, Mudra H, Hochadel M, Schneider S, Senges J, Akin I. Left atrial appendage closure in patients with a reduced left ventricular ejection fraction: results from the multicenter German LAARGE registry. Clin Res Cardiol. 2020 Nov;109(11):1333-1341. doi: 10.1007/s00392-020-01627-8. Epub 2020 Mar 31.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LAARGE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.